The supply deal has been signed to support RNA-based programmes to treat Duchenne muscular dystrophy
Johnson Matthey (JM) has entered into a five-year supply agreement with Sarepta Therapeutics to continue supplying regulatory starting materials to support Sarepta's phosphorodiamidate morpholino oligomer (PMO) and peptide phosphorodiamidate morpholino oligomer (PPMO) programmes used for the treatment of Duchenne Muscular Dystrophy.
Sarepta is the leader in precision genetic medicine for rare diseases and working to change the lives of people living with rare diseases. Johnson Matthey's Innovator Products & Solutions business that provides Custom Development and Manufacturing Services (CDMO) will produce these synthetic regulatory starting materials at their facilities in West Deptford, NJ and Devens, MA using their commercial-scale production trains.
"JM is delighted to further strengthen our relationship with Sarepta through this manufacturing agreement," said Alex Zahiri, VP of Innovator Products & Solutions (CDMO) business, Johnson Matthey. "Our collaboration with Sarepta signifies our continued commitment to existing and future PPMO and PMO programs, and Sarepta's mission of engineering precision medicine for rare, devastating diseases."
"Sarepta's growing pipeline requires best in class manufacturing expertise in order to deliver on our commitment to patients. We are excited to expand and extend our agreement with Johnson Matthey as a manufacturing partner for our PMO and PPMO platforms," said Bill Ciambrone, Executive VP of Technical Operations, Sarepta.
As leaders in the complex technologies behind a wide variety of healthcare products and services, Johnson Matthey provides its global customers with expertise in complex active pharmaceutical ingredient development and manufacture, solid form sciences, particle engineering, and catalysts. JM uses its cutting-edge science to create solutions that improve healthcare and make a real difference to the world around us.